This morning, GlaxoSmithKline defended its controversial diabetes drug, Avandia, in front of a panel of federal advisers convened to decide whether the pill causes heart attacks.
The panel will help the U.S. Food and Drug Administration decide whether steps should be taken to limit sales of Avandia. Some of Glaxo's defenses were met with skepticism, and new information emerged tarring the diabetes pill. Glaxo itself said that new language on the drug's heart risks should be added to its packaging. In slides made public this morning, David Graham, an FDA drug safety expert, recommends that Avandia should be pulled from the market.